macro

Savara stock drops after FDA misses review deadline for lung therapy

Savara shares lost 17% to $4.31 after the FDA said it would not meet its November 22 target date for molgramostim, according to Dow Jones Newswires.

the same feed is available to bots and dashboards through the api. connect the api →

what happened

Savara shares fell 17% to $4.31 in late morning trading on Friday, according to Dow Jones Newswires, and are down 28% so far this year.

The company said the US regulator informed it that the agency will not reach a decision by its target date of Sunday, November 22, on the biologics license application for molgramostim, an inhaled therapy Savara makes for a rare lung disease.

Savara added that the review is still ongoing and that no revised action date has been provided.

why it matters

For investors, the key question is timing: a regulatory delay with no new date keeps the launch of a single-product drug uncertain, which explains the sell-off. The story is company-specific, so its reach beyond small-cap biotech stocks is limited.

tags

instruments

Savara shares

sources

  1. Savara Shares Tumble, FDA to Miss Target Date for License of Lung Disease Treatment — Dow Jones Newswires, 20 November 2026 at 16:42 UTC

prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.

alerts on your topics, the morning digest and the api — in your account.

get stories in real time ↗